Latigo (LTGO) upsizes IPO to $397.4M, extends cash runway
Latigo Biotherapeutics upsized its IPO to $397.4 million, extending its cash runway into 2029. Phase 2 results for onzotrigine in acute pain were published in NEJM; Phase 3 trials are planned.